Antithrombotic therapy with rivaroxaban in five patients with paroxysmal nocturnal haemoglobinuria and thrombotic events
Abstract Five patients with paroxysmal nocturnal haemoglobinuria and thrombotic complications under oral antithrombotic treatment with vitamin K antagonist were switched to receive the direct oral anticoagulant rivaroxaban an factor Xa inhibitor. In all five patients haematological and biochemical p...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2018-10-01
|
| Series: | Thrombosis Journal |
| Subjects: | |
| Online Access: | http://link.springer.com/article/10.1186/s12959-018-0181-5 |
| id |
doaj-925bf0965194422db1ec9afe595689b7 |
|---|---|
| record_format |
Article |
| spelling |
doaj-925bf0965194422db1ec9afe595689b72020-11-24T21:46:43ZengBMCThrombosis Journal1477-95602018-10-011611410.1186/s12959-018-0181-5Antithrombotic therapy with rivaroxaban in five patients with paroxysmal nocturnal haemoglobinuria and thrombotic eventsFrancesco Dragoni0Flavia Chiarotti1Anna Paola Iori2Ursula La Rocca3Arturo Cafolla4Thrombosis Center, “Department of Cellular Biotechnologies and Hematology”, “Sapienza” UniversityReference Center for Behavioral Sciences and Mental Health, National Institute of HealthThrombosis Center, “Department of Cellular Biotechnologies and Hematology”, “Sapienza” UniversityThrombosis Center, “Department of Cellular Biotechnologies and Hematology”, “Sapienza” UniversityThrombosis Center, “Department of Cellular Biotechnologies and Hematology”, “Sapienza” UniversityAbstract Five patients with paroxysmal nocturnal haemoglobinuria and thrombotic complications under oral antithrombotic treatment with vitamin K antagonist were switched to receive the direct oral anticoagulant rivaroxaban an factor Xa inhibitor. In all five patients haematological and biochemical parameters and adverse events were evaluated for a period of twelve months. Therapy with rivaroxaban was well tolerated in all cases and one patient showed a significant reduction of bleeding and transfusion requirement. All patients obtained a significant reduction in days of hospitalization with a consequent improvement in their quality of life after rivaroxaban treatment.http://link.springer.com/article/10.1186/s12959-018-0181-5Paroxysmal nocturnal haemoglobinuriaAntithrombotic therapyRivaroxabanVitamin K antagonistThrombotic events |
| collection |
DOAJ |
| language |
English |
| format |
Article |
| sources |
DOAJ |
| author |
Francesco Dragoni Flavia Chiarotti Anna Paola Iori Ursula La Rocca Arturo Cafolla |
| spellingShingle |
Francesco Dragoni Flavia Chiarotti Anna Paola Iori Ursula La Rocca Arturo Cafolla Antithrombotic therapy with rivaroxaban in five patients with paroxysmal nocturnal haemoglobinuria and thrombotic events Thrombosis Journal Paroxysmal nocturnal haemoglobinuria Antithrombotic therapy Rivaroxaban Vitamin K antagonist Thrombotic events |
| author_facet |
Francesco Dragoni Flavia Chiarotti Anna Paola Iori Ursula La Rocca Arturo Cafolla |
| author_sort |
Francesco Dragoni |
| title |
Antithrombotic therapy with rivaroxaban in five patients with paroxysmal nocturnal haemoglobinuria and thrombotic events |
| title_short |
Antithrombotic therapy with rivaroxaban in five patients with paroxysmal nocturnal haemoglobinuria and thrombotic events |
| title_full |
Antithrombotic therapy with rivaroxaban in five patients with paroxysmal nocturnal haemoglobinuria and thrombotic events |
| title_fullStr |
Antithrombotic therapy with rivaroxaban in five patients with paroxysmal nocturnal haemoglobinuria and thrombotic events |
| title_full_unstemmed |
Antithrombotic therapy with rivaroxaban in five patients with paroxysmal nocturnal haemoglobinuria and thrombotic events |
| title_sort |
antithrombotic therapy with rivaroxaban in five patients with paroxysmal nocturnal haemoglobinuria and thrombotic events |
| publisher |
BMC |
| series |
Thrombosis Journal |
| issn |
1477-9560 |
| publishDate |
2018-10-01 |
| description |
Abstract Five patients with paroxysmal nocturnal haemoglobinuria and thrombotic complications under oral antithrombotic treatment with vitamin K antagonist were switched to receive the direct oral anticoagulant rivaroxaban an factor Xa inhibitor. In all five patients haematological and biochemical parameters and adverse events were evaluated for a period of twelve months. Therapy with rivaroxaban was well tolerated in all cases and one patient showed a significant reduction of bleeding and transfusion requirement. All patients obtained a significant reduction in days of hospitalization with a consequent improvement in their quality of life after rivaroxaban treatment. |
| topic |
Paroxysmal nocturnal haemoglobinuria Antithrombotic therapy Rivaroxaban Vitamin K antagonist Thrombotic events |
| url |
http://link.springer.com/article/10.1186/s12959-018-0181-5 |
| work_keys_str_mv |
AT francescodragoni antithrombotictherapywithrivaroxabaninfivepatientswithparoxysmalnocturnalhaemoglobinuriaandthromboticevents AT flaviachiarotti antithrombotictherapywithrivaroxabaninfivepatientswithparoxysmalnocturnalhaemoglobinuriaandthromboticevents AT annapaolaiori antithrombotictherapywithrivaroxabaninfivepatientswithparoxysmalnocturnalhaemoglobinuriaandthromboticevents AT ursulalarocca antithrombotictherapywithrivaroxabaninfivepatientswithparoxysmalnocturnalhaemoglobinuriaandthromboticevents AT arturocafolla antithrombotictherapywithrivaroxabaninfivepatientswithparoxysmalnocturnalhaemoglobinuriaandthromboticevents |
| _version_ |
1725900416262078464 |